Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Mineralys Therapeutics, Inc. (MLYS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $28.90, with a market capitalisation of $2.56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.30 to $47.65. This page covers its latest market performance, valuation, price trends and company information.
$2.56B | |
$28.90 | |
$47.65 | |
$5.85 | |
$28.91 | |
1.00 | |
1.12M | |
-- | |
$47.65 | |
$22.30 | |
-- | |
-- |
Mineralys Therapeutics, Inc. (MLYS) is trading at $28.90 in pre-market trading as of 2026-09-16 08:53:00, down 0.05% ($0.02) from the previous close of $28.91
Pre-market trading shows how investors are pricing MLYS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Mineralys Therapeutics, Inc. (MLYS) moved from $28.21 to $28.90, representing a gain of 2.43% ($0.68).
The stock traded between $27.40 and $31.99 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 1.54 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 26.0%
MLYS is currently trading at $28.90, placing it 26.0% of the way from its 52-week low of $22.30 to its 52-week high of $47.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 76 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mineralys Therapeutics, Inc. (MLYS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.